Admission: Spectral MD Holdings Ltd
Spectral is a predictive analytics group that develops proprietary AI algorithms and optical technology. It helps clinicians make more accurate and faster treatment decisions in the wound care sector.
Spectral is able to distinguish between damaged and healthy human tissue invisible to the naked eye, providing 'Day One' healing assessments for burn wounds and diabetic foot ulcers. This is aided by its internally developed DeepView® Wound Imaging Solution, an AI technology and multispectral imaging system which has designated FDA Breakthrough Device.
Spectral has received substantial support from the U.S. government with contracts from institutions such as Biomedical Advanced Research and Development Authority, National Science Foundation and Defense Health Agency in support of the burns application for its DeepView® system.
Crowe's role and team
Crowe acted as the reporting accountant on the transaction. The capital markets team was led by Mitesh Patelia, George Lawford and Conor Monaghan.
Client quote
The Capital Markets team at Crowe were extremely professional and efficient throughout the transaction. This deal marks an important step in our growth strategy and would certainly recommend them to other US companies looking to list on AIM.
Wensheng Fan, Chief Executive Officer, Spectral MD Holdings, Ltd
